Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to $582,000.

  • Inhibrx Biosciences' Depreciation & Amortization (CF) fell 23.42% to $582,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 37.77%. This contributed to the annual value of $2.3 million for FY2024, which is 91.86% up from last year.
  • Inhibrx Biosciences' Depreciation & Amortization (CF) amounted to $582,000 in Q3 2025, which was down 12.08% from $662,000 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Depreciation & Amortization (CF) ranged from a high of $760,000 in Q3 2024 and a low of $294,000 during Q2 2023.
  • Over the past 3 years, Inhibrx Biosciences' median Depreciation & Amortization (CF) value was $528,500 (recorded in 2024), while the average stood at $509,900.
  • Per our database at Business Quant, Inhibrx Biosciences' Depreciation & Amortization (CF) soared by 150.00% in 2024 and then dropped by 23.42% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Depreciation & Amortization (CF) stood at $298,000 in 2023, then spiked by 131.21% to $689,000 in 2024, then dropped by 23.42% to $582,000 in 2025.
  • Its last three reported values are $582,000 in Q3 2025, $662,000 for Q2 2025, and $675,000 during Q1 2025.